Is Saakshi Medtech overvalued or undervalued?

As of 22 August 2025, Saakshi Medtech's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its perceived value. The company is currently considered overvalued based on its high valuation ratios, including a PE ratio of 72.10, an EV to EBITDA of 33.18, and a Price to Book Value of 3.64. These figures suggest that the market is pricing the stock significantly above its fundamental value.
In comparison to its peers, Saakshi Medtech's PE ratio is higher than Adani Enterprises at 78.81 and SRF at 60.41, both of which are also classified as expensive or very expensive. Notably, Tata Chemicals, which is rated attractive, has a much lower PE ratio of 53.91, indicating that Saakshi Medtech may not justify its current price level. Additionally, the company's recent stock performance has been underwhelming, with a year-to-date return of -12.75%, contrasting sharply with the Sensex's gain of 5.18% over the same period. This further reinforces the view that Saakshi Medtech is overvalued in the current market environment.